Minerva Neurosciences | NERV - Gastos De Venta Y Administración





Gastos De Venta Y Administración Cambio Fecha
Acadia Pharmaceuticals USD 160.79M 14.06M 2026-03
Adma Biologics USD 20.19M 2.86M 2025-12
ALKERMES USD 264.59M 77.4M 2026-03
Alterity Therapeutics Limited AUD 1.45M 703.96K 2025-12
AstraZeneca USD 5.06B 455M 2026-03
BioCryst Pharmaceuticals USD 95.78M 12.77M 2025-12
Bristol-Myers Squibb USD 1.62B 564M 2026-03
Cipla INR 13.25B 101.8M 2025-12
Clal Biotechnology ILS 3.31M 513K 2022-12
Compugen USD 2.21M 120K 2025-12
CSL USD 1.23B 498M 2025-12
Eli Lilly USD 2.93B 198M 2026-03
Esperion Therapeutics USD 39.42M 456K 2025-12
GlaxoSmithKline GBP 2.12B 558M 2026-03
Grifols EUR 320.45M 12.65M 2025-12
Halozyme Therapeutics USD 46.29M 18.35M 2026-03
Ionis Pharmaceuticals USD 151M 21M 2026-03
J&J USD 6.03B 719M 2026-03
Merck USD 2.67B 180M 2026-03
Minerva Neurosciences USD 2.48M 58.79K 2024-09
Neurocrine Biosciences USD 318.5M 16.7M 2026-03
Novartis USD 3.14B 296M 2026-03
Novavax USD 25.53M 1.34M 2025-12
Pfizer USD 2.92B 1.16B 2026-03
Roche Holding CHF 7.28B 3.99B 2025-12
Sanofi EUR 2.33B 419M 2026-03
Takeda JPY 292B 9.21B 2026-03
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12